A phase I/II study of ABT-888 in combination with 5-fluorouracil (5-FU) and oxaliplatin (Ox) in patients with metastatic pancreatic cancer (MPC).
Michael J. Pishvaian(The University of Texas MD Anderson Cancer Center), Jonathan R. Brody(Oregon Health & Science University), Aiwu Ruth He(Georgetown University), Louis M. Weiner(Georgetown University), Susan J. Littman(Thomas Jefferson University), John L. Marshall(Vince Lombardi Cancer Clinic), Keisha White(Georgetown University), Tingting Zhuang(Shantou University), Hongkun Wang(Georgetown University), Jimmy J. Hwang(University of California, San Francisco), Lisa Ley(National Cancer Institute), Amy Hankin(National Institutes of Health)
Cited by 24
Related Papers
The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
|Clinical Cancer Research|2009|1.4k
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma
|Nature|2011|1.3k
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
|NEJM Evidence|2022|1.1k
Monoclonal Antibodies in Cancer Therapy
|Antibodies|2020|799